• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Lower vs Higher Glycemic Criteria for Diagnosing GDM

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Australia and New Zealand uses the ‘one step’ GDM screening approach, but adopted a higher glycemic threshold than the IADPSG recommendation
  • Crowther et al. (NEJM, 2022) assessed whether the detection of gestational diabetes mellitus (GDM) using lower vs higher glycemic criteria would lead to lower perinatal morbidity

METHODS:

  • Randomized trial
    • 2 district health boards in New Zealand
  • Participants
    • Singleton pregnancy between 24 to 32 weeks
    • Had a 75-g oral glucose-tolerance test (OGTT) for GDM (‘one step’)
  • Intervention
    • Lower glycemic criteria
      • Fasting plasma glucose level of at least 92 mg per deciliter (≥5.1 mmol per liter) or
      • A 1-hour level of at least 180 mg per deciliter (≥10.0 mmol per liter) or
      • A 2-hour level of at least 153 mg per deciliter (≥8.5 mmol per liter)
    • Higher glycemic criteria
      • Fasting plasma glucose level of at least 99 mg per deciliter (≥5.5 mmol per liter) or
      • A 2-hour level of at least 162 mg per deciliter (≥9.0 mmol per liter)
  • Primary outcome
    • Large for gestational age (LGA) infant
      • Birth weight >90th percentile according to Fenton–WHO standards
  • Secondary outcomes
    • Maternal and infant health

RESULTS:

  • Lower glycemic criteria: 2022 women | Higher glycemic criteria: 2039
    • Infants born to women in the lower group: 2019
    • Infants born to women in the higher group: 2031
  • GDM diagnoses were higher using lower glycemic criteria
    • Lower glycemic criteria: 15.3%
    • Higher glycemic criteria: 6.1%
  • There was no significant difference in risk for LGA among lower vs higher glycemic criteria groups
    • Higher glycemic criteria: 8.8%
    • Lower glycemic criteria: 8.9%
    • Adjusted relative risk (aRR) 0.98 (95% CI, 0.80 to 1.19); P=0.82
  • The following were more common in the lower glycemic criteria group
    • Use of health services
    • Use of pharmacologic agents
    • Neonatal hypoglycemia
  • Maternal and infant health were generally similar between the two groups
  • There was no differences in adverse effects between the groups
  • Among the women in both groups who had glucose test results that fell between the lower and higher glycemic criteria
    • Those who were treated for GDM (195 women) benefitted and had fewer large for gestational age infants than those who were not treated (178 women)

CONCLUSION:

  • Using lower GDM glycemic criteria (IADPSG) did not improve pregnancy outcomes or lower the risk of large for gestational age infants vs higher glycemic criteria (current Australia & New Zealand standard)
  • The authors state

Two previous randomized trials have compared the IADPSG criteria with the Carpenter–Coustan screening criteria, but data from trials comparing the IADPSG criteria with the criteria currently recommended for use in New Zealand are lacking

Both previous trials showed that there were more women who received a diagnosis of gestational diabetes with the IADPSG criteria than with the Carpenter–Coustan screening criteria but that there was no improvement in perinatal health

Overall, the risks of giving birth to a large-for-gestational-age infant and of other infant or maternal complications were not lower with the lower glycemic criteria than with the higher glycemic criteria

Learn More – Primary Sources:

Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

ScreenR2GDM RCT Results: One-Step vs Two-Step Screening for GDM?
How Have Rates of Gestational Diabetes Changed in the Last Decade Across Race and Ethnicity Subgroups?
Meta-Analysis: Adverse Pregnancy Outcomes associated with GDM Following Adjustment for Confounding Factors

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site